C-MYC AND C-MYB EXPRESSION IN ACUTE MYELOGENOUS LEUKEMIA

被引:21
|
作者
GOPAL, V
HULETTE, B
LI, YQ
KUVELKAR, R
RAZA, A
LARSON, R
GOLDBERG, J
TRICOT, G
BENNETT, J
PREISLER, H
机构
[1] UNIV CINCINNATI,MED CTR,K PAVIL,ML 508,231 BETHESDA AVE,CINCINNATI,OH 45267
[2] INDIANA UNIV PENN,MED CTR,INDIANA,PA 15701
[3] UNIV ROCHESTER,ROCHESTER,NY 14627
[4] UNIV CHICAGO,CHICAGO,IL 60637
[5] COOPER HOSP UNIV MED CTR,CAMDEN,NJ
关键词
C-MYC; C-MYB; AML;
D O I
10.1016/0145-2126(92)90080-Q
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Monoclonal antibodies and flow cytometry were used to detect the expression of c-myc and c-myb in the bone marrow (BM) and peripheral blood (PB) cells of patients with acute myelogenous leukemia (AML). The expression of neither gene was correlated with the percent blast cells in the BM or PB nor was there a correlation between c-myc and c-myb expression. A wide range of expression of each gene was found within each FAB type of AML. Patients who had a high proportion of leukemia cells expressing c-myb were less likely to respond to remission induction therapy than patients in whom a low proportion of cells expressed c-myb. This association appears to reflect an inverse relationship between the proportion of cells expressing c-myb and the sensitivity of leukemia cells to the killing effects of chemotherapy in vivo. Treatment outcome was unrelated to c-myc expression.
引用
收藏
页码:1003 / 1011
页数:9
相关论文
共 50 条
  • [21] TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) WITH C-MYB ANTISENSE OLIGODEOXYNUCLEOTIDES
    GEWIRTZ, AM
    BONE MARROW TRANSPLANTATION, 1994, 14 : S57 - S61
  • [22] Double minutes and c-MYC amplification in acute myelogenous leukemia:: Are they prognostic factors?
    Bruckert, P
    Kappler, R
    Scherthan, H
    Link, H
    Hagmann, FG
    Zankl, H
    CANCER GENETICS AND CYTOGENETICS, 2000, 120 (01) : 73 - 79
  • [23] MACROPHAGE PRIMING AND ACTIVATION DURING FIBROSARCOMA GROWTH - EXPRESSION OF C-MYB, C-MYC, C-FOS, AND C-FMS
    ALLEVA, DG
    ASKEW, D
    BURGER, CJ
    ELGERT, KD
    IMMUNOLOGICAL INVESTIGATIONS, 1994, 23 (6-7) : 457 - 472
  • [24] GLUCOCORTICOID INHIBITION OF C-MYC, C-MYB, AND C-KI-RAS EXPRESSION IN A MOUSE LYMPHOMA CELL-LINE
    EASTMANREKS, SB
    VEDECKIS, WV
    CANCER RESEARCH, 1986, 46 (05) : 2457 - 2462
  • [25] EXPRESSION OF C-MYC, C-MYB, AND C-SIS PROTOONCOGENES IN FIBROBLASTS FROM AFFECTED AND UNAFFECTED SKIN OF PATIENTS WITH SYSTEMIC
    FEGHALI, CA
    BOULWARE, DW
    FERRISS, JA
    LEVY, LS
    ARTHRITIS AND RHEUMATISM, 1992, 35 (09): : S345 - S345
  • [26] Activation of c-MYC in Acute Leukemia
    Bhagavathi, S.
    Aviv, H.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2012, 14 (06): : 663 - 663
  • [27] C-MYB BUT NOT C-MYC SUPPRESSES THE HEMIN-INDUCED NONTERMINAL EXPRESSION OF HEMOGLOBIN BY MURINE ERYTHROLEUKEMIA-CELLS
    PROCHOWNIK, EV
    BLOOD, 1989, 73 (03) : 782 - 786
  • [28] REGULATION OF TRANSCRIPTION FACTORS C-MYC, MAX, AND C-MYB BY CASEIN KINASE-II
    BOUSSET, K
    OELGESCHLAGER, MHH
    HENRIKSSON, M
    SCHREEK, S
    BURKHARDT, H
    LITCHFIELD, DW
    LUSCHERFIRZLAFF, JM
    LUSCHER, B
    CELLULAR & MOLECULAR BIOLOGY RESEARCH, 1994, 40 (5-6) : 501 - 511
  • [29] INHIBITION OF INTIMAL HYPERPLASIA BY ANTISENSES C-MYC AND C-MYB IS MODULATED BY THE DURATION OF THE OLIGONUCLEOTIDES DELIVERY
    SIROIS, MG
    ELAZER
    EDELMAN, R
    SIMONS, M
    ROSENBERG, RD
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 303 - 303
  • [30] EXPRESSION OF C-MYC, C-MYB, AND C-SIS IN FIBROBLASTS FROM AFFECTED AND UNAFFECTED SKIN OF PATIENTS WITH SYSTEMIC-SCLEROSIS
    FEGHALI, CA
    BOULWARE, DW
    FERRISS, JA
    LEVY, LS
    AUTOIMMUNITY, 1993, 16 (03) : 167 - 171